2019
DOI: 10.1007/s40265-019-01128-7
|View full text |Cite
|
Sign up to set email alerts
|

Medical Management of Cushing’s Syndrome: Current and Emerging Treatments

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
37
0
3

Year Published

2019
2019
2023
2023

Publication Types

Select...
6
1
1

Relationship

3
5

Authors

Journals

citations
Cited by 42 publications
(40 citation statements)
references
References 137 publications
0
37
0
3
Order By: Relevance
“…Medical therapy is classified into steroidogenesis inhibitors (ketoconazole, metyrapone, mitotane, etomidate), centrally acting agents (cabergoline, pasireotide, pasireotide LAR, temozolomide) and glucocorticoid receptor (GR) antagonists (mifepristone). New treatment options such as oxylodrostat and levoketoconazole (steroidogenesis inhibitors), relacorilant (a glucocorticoid receptor antagonist) and drugs targeting corticotroph adenomas (retinoic acid, epidermal growth factor receptor inhibitors, cyclin-dependent kinases inhibitors, and heat shock protein 90 inhibitors, monoclonal antibodies against ACTH) are also being investigated [59,60]. Medical treatment is promising with current drug studies, consequently, it can also be preferred as an alternative treatment.…”
Section: Gks N ( %)mentioning
confidence: 99%
“…Medical therapy is classified into steroidogenesis inhibitors (ketoconazole, metyrapone, mitotane, etomidate), centrally acting agents (cabergoline, pasireotide, pasireotide LAR, temozolomide) and glucocorticoid receptor (GR) antagonists (mifepristone). New treatment options such as oxylodrostat and levoketoconazole (steroidogenesis inhibitors), relacorilant (a glucocorticoid receptor antagonist) and drugs targeting corticotroph adenomas (retinoic acid, epidermal growth factor receptor inhibitors, cyclin-dependent kinases inhibitors, and heat shock protein 90 inhibitors, monoclonal antibodies against ACTH) are also being investigated [59,60]. Medical treatment is promising with current drug studies, consequently, it can also be preferred as an alternative treatment.…”
Section: Gks N ( %)mentioning
confidence: 99%
“…The cost of treatment for patients taking PEG is high [79]; exceeding that of SRLs by 3-4 times [79,80]. A combination of PEG and other medications, however, might allow for cost-effective therapy, due to a reduced PEG dose [7,20,77,[81][82][83][84][85][86][87][88][89][90] (▶ table 3).…”
Section: Acromegalymentioning
confidence: 99%
“…Moreover, up to 35 % of patients in apparent remission will relapse within 10 years or more [119,120]. For patients with persistent disease there are several options [109]: repeat surgery (with lower efficacy of around 60 % of cases), radiotherapy (adenoma-targeted or whole sellar stereotactic radiosurgery), with a 54-75 % efficacy at 5 years and a 20-30 % recurrence rate [41,121], medical treatment [85], a combination of the above or bilateral adrenalectomy (the latter having a 10-30 % risk of inducing Nelson's syndrome) [122].…”
Section: Cushing's Diseasementioning
confidence: 99%
See 1 more Smart Citation
“…However, the obvious disadvantage of this procedure is the subsequent permanent hypoadrenalism, which requires lifetime hormone replacement therapy (Chow et al, 2008). Medical therapy plays a secondary role to the previous alternatives in the management of CS, where it is used in severe cases of hypercortisolism to lower anaesthetic risk for a given surgical procedure or to diminish clinical afflictions during the latency period for remission in radiotherapy (Mancini, Porcelli &Giustina, 2010 andHinojosa-Amaya, Cuevas-Ramos, &Fleseriu, 2019).…”
Section: Therapeutic Principles In Cushing's Syndromementioning
confidence: 99%